The biosimilar erythropoiesis-stimulating agent (ESA) epoetin was well-tolerated and efficacious in the treatment of geriatric patients with chemotherapy-induced anemia (CIA), a recent study found.
CIA is a common complication among cancer patients, particularly older individuals. Biosimilar ESAs can lower the costs of supportive cancer treatments for this patient population. In a subanalysis published in Dove Press, investigators compared the efficacy and tolerability of an epoetin biosimilar for the treatment of CIA in patients <70 years versus patients ≥70 years.
Patients with CIA (hemoglobin [Hb] <11 g/dL) in association with chemotherapy for solid tumors, lymphoma, or myeloma, were enrolled in the ORHEO observational trial. Participants were administered an epoetin biosimilar, and were evaluated at 3 and 6 months for a response.
A response was defined in the study as achieving target Hb without blood transfusions during the 3 weeks preceding measurement, Hb ≥10 g/dL, or Hb increase ≥1 g/dL since study enrollment.
The secondary endpoints were changes in Hb level, transfusion rates, treatment interruptions, and adverse events (AEs), according to the study.
All statistical analyses were conducted on the per protocol population, which excluded patients with missing baseline Hb values, patients for whom age was not recorded, patients who had not initiated chemotherapy at baseline, patients who were not receiving an epoetin biosimilar at baseline, and patients who switched to another epoetin treatment between baseline and 6 months.
ORHEO is a large, observational, non-interventional, longitudinal, national, multi-center study that included 2333 patients from 235 centers.
Read more: www.specialtypharmacytimes.com
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Annual STADA Report Shows Record Profit Growth for 2023
March 25th 2024Germany-based biosimilar manufacturer STADA Arzneimittel reports strong financial performance in 2023 with double digit sales growth and billions in profits. The CEO credits the company’s success on their strong company culture and focus for innovation.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Physician and Patient Perspectives After Starting or Switching to Amgevita in IBD
March 23rd 2024A real-world study surveying physicians and patients on adalimumab biosimilar ABP 501 (Amgevita) in inflammatory bowel disease (IBD) found both patients initiating ABP 501 and those who had switched from the reference product had higher satisfaction levels.